5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.

ABSTRACT:

Background and aims

The objective of this study was to evaluate the risk of colorectal cancer (CRC) in patients taking aminosalicylates (5-ASA) for inflammatory bowel disease (IBD).

Methods

The General Practice Research Database (GPRD) which contains the primary care records of five million people in the UK was used to identify users of mesalazine, balsalazide, olsalazine, or sulfasalazine with a history of IBD. In a nested case control analysis, each incident CRC case with any use of a 5-ASA in the six months before the CRC diagnosis was matched by age, sex, and calendar time to six control patients who were also currently using a 5-ASA. Patients were then classified according to regularity of use. The analysis was controlled for body mass index, IBD duration, history of co

SUBMITTER: van Staa TP 

PROVIDER: S-EPMC1774734 | biostudies-literature | 2005 Nov

REPOSITORIES: biostudies-literature